# Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)

> **NCT02368119** · PHASE1 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 60 (actual)

## Conditions studied

- Ebola Virus Disease
- Hemorrhagic Fever

## Interventions

- **BIOLOGICAL:** VRC-EBOADC069-00-vp
- **BIOLOGICAL:** VRC-EBOADC069-00-vp
- **BIOLOGICAL:** MVA-EbolaZ
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02368119
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2016-09-27
- **Final completion:** 2016-09-27
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02368119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02368119, "Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02368119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*